This approach, which combined dabrafenib–trametinib or vemurafenib–cobimetinib, received FDA approvals in 2014 and 2015, respectively, for treating unresectable or metastatic melanoma with BRAF mutations. Here, BRAF is linked to metastatic melanoma.